What is the efficacy of Pfizer Paciclovir? What role does it play in fighting the epidemic?

Recently, some media reported that Pfizer announced that its oral antiviral drug PAXLOVID reduced the risk of hospitalization or death by 89%. Paciclovir is the first oral antiviral drug developed by Huirui Laboratory, and it is a specially designed novel coronavirus -3CL protease inhibitor, which can effectively inhibit the replication of COVID-19, thus treating COVID-19. The author sorted out the relevant data and found that the practical application effect of oral antiviral drugs of paciclovir is not ideal, as follows.

First of all, there were 2 102 patients in the second and third phase clinical trials of oral antiviral drugs of paciclovir. From the point of view of drug clinical trials, the number of clinical samples is too small and unconvincing, so the number of samples should be increased. In the second and third phase clinical trials, the observation period of only drugs and placebos is 28 days, and the therapeutic effect is limited to no serious illness or death within 28 days. However, the actual situation of patients after 28 years has not been counted, and the clinical trials are not comprehensive and lack of long-term observation.

Secondly, according to the relevant data of South Korea, after you introduced this batch of drugs, you found that 8000 elderly people died in COVID-19 within two months after you stopped using them for people over 65, so the curative effect is questionable. Jan Gerstoft, a professor of infectious diseases in Rigshospitalet, Denmark, a European country, even bluntly said that "the effect of these tablets (PAXLOVID) is very limited, if any", so the role of Paxlovid oral antiviral drugs in fighting the epidemic is very limited.

Third, the sales data of oral antiviral drugs of paciclovir in the United States are not ideal. It is widely expected that the sales of paroxetine in the United States in the first quarter was $654.38+09 billion, but it was later adjusted to $654.38+04 billion. According to the actual effect and sales situation, the latest forecast is $350 million.

Therefore, to sum up, the effect of oral antiviral drugs of paciclovir in the epidemic situation is actually limited.